ARTICLE IN PRESS. Ticks and Tick-borne Diseases
|
|
- Millicent Adams
- 6 years ago
- Views:
Transcription
1 Ticks and Tick-borne Diseases 1 (2010) Contents lists available at ScienceDirect Ticks and Tick-borne Diseases journal homepage: Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi Louis Ates a, c, Christa Hanssen-Hübner a, Douglas E. Norris b, Dania Richter d, Peter Kraiczy a, Klaus-Peter Hunfeld c, a Institute of Medical Microbiology and Infection Control, University Hospital of Frankfurt, Frankfurt/Main, Germany b The Harry W. Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland c Institute of Laboratory Medicine, Northwest Medical Centre, Academic Teaching Hospital, Medical Faculty, University of Frankfurt, Steinbacher Hohl 2 26, D Frankfurt/Main, Germany d Abt. Parasitologie, Institut für Pathologie, Charité Universitätsmedizin Berlin, Malteserstrasse , Berlin, Germany article info Article history: Received 23 August 2009 Received in revised form 22 November 2009 Accepted 23 November 2009 Available online 7 January 2010 Keywords: Borrelia burgdorferi Tetracyclines Tigecycline Susceptibility testing Lyme borreliosis abstract Tigecycline is a new glycylcycline that has recently been revealed to be very effective in vitro against a variety of Gram-negative and Gram-positive bacteria including multi-drug resistant microorganisms. Using a standardized microdilution susceptibility testing method, we determined the minimal inhibitory concentrations (MICs) and the minimal bactericidal concentrations (MBCs) of tigecycline, in parallel with doxycycline, tetracycline, and other antibiotic agents relevant for Lyme borreliosis treatment such as ceftriaxone and cefotaxime. The activity of all agents against 16 different Borrelia isolates belonging to all borrelial genospecies known to be pathogenic for humans was investigated and analyzed under standardized conditions. The overall rank order of MIC 90 s was tigecycline (r0.016 mg/l) 4 ceftriaxone (0.03 mg/l) 4 cefotaxime (r0.125 mg/l) 4 doxycycline (0.25 mg/l) 4 tetracycline (0.25 mg/l). The rank order of MBC 90 s was tigecycline (0.5 mg/l) 4 ceftriaxone (2 mg/l) 4 tetracycline (16 mg/l) 4 doxycycline (16 mg/l) 4 cefotaxime (416 mg/l). High in vitro activity of the new glycylcycline against Borrelia was further substantiated by time-kill experiments performed with B. afzelii isolate EB1. Parallel testing of tigecycline and ceftriaxone demonstrated a bacteriostatic effect for mg/l of tigecycline and for 0.03 mg/l for ceftriaxone after 72 h of incubation. Moreover, tigecycline was bactericidal at a concentration of 0.25 mg/l showing a 43 log 10 unit reduction of the initial inoculum, whereas for ceftriaxone a concentration of 2 mg/l was needed. & 2009 Elsevier GmbH. All rights reserved. Introduction Lyme borreliosis is a vector-borne disease that is transmitted by ixodid ticks and is caused by the spirochete Borrelia burgdorferi sensu lato (s.l.) complex. The 5 genospecies that are currently considered to be human pathogens are B. burgdorferi sensu stricto (s.s.), B. afzelii, B. garinii, and B. spielmanii, and the proposed but not yet validated novel species B. bavariensis (Margos et al., 2009). In Europe, the incidence of Lyme borreliosis is estimated to range from 3.9 to 168/ 100,000 (Hunfeld et al., 2005; Stanek et al., 1996). The disease can manifest itself progressively as a multisystem disorder exhibiting a large variety of clinical symptoms (Steere, 2001). Early on in the course of the infection, a bull s-eye rash called erythema migrans is the most common disease manifestation appearing in 80 90% of the patients. If left untreated, however, the infection may cause Corresponding author. Tel.: ; fax: address: K.Hunfeld@em.uni-frankfurt.de (K.-P. Hunfeld). neurological disorders and late manifestations including acrodermatitis chronica atrophicans or chronic arthritis (Steere, 2001; Weinstein and Britchkov, 2002). Lyme borreliosis is frequently treated by orally administered doxycycline or intravenous ceftriaxone, which appear to be equally effectiveineuropeanpatients(ljostad et al., 2008; Loewen et al., 1999). Other often administered antibiotics are penicillin, amoxicillin, cefuroxime, cefotaxime, and tetracycline. Although these drugs have been reported to be clinically effective in the majority of cases under controlled study conditions, treatment failures have been repeatedly published for most of these compounds (Hodzic et al., 2008; Hunfeld et al., 2005; Miklossy et al., 2008; Preac-Mursic et al., 1989). Tigecycline, a glycylcycline and structural analog of minocycline is a relatively new antibiotic agent that has been found to be effective against many Gram-positive and Gram-negative bacteria including multi-drug resistant pathogens such as ESBL-producing enterobacteriaceae, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and multi-drug resistant Acinetobacter baumanii (Jamal et al., 2009; Zhanel et al., X/$ - see front matter & 2009 Elsevier GmbH. All rights reserved. doi: /j.ttbdis
2 L. Ates et al. / Ticks and Tick-borne Diseases 1 (2010) ). Tigecycline is a primarily bacteriostatic agent that binds to thebacterial30ssubunitofthebacterialribosome(greer, 2006). Recently, tigecycline was also found to be effective in vitro against several strains of B. burgdorferi s.l. (Yang et al., 2009). However, the number of isolates tested in this study was small and so far tigecycline has not been tested in parallel with other tetracyclines against borreliae under well-controlled conditions. In this study, we used a well-evaluated and standardized methodology to investigate the in vitro activity and bactericidal properties of tigecycline against 16 isolates of the B. burgdorferi s.l. complex in comparison to a series of compounds relevant for the treatment of Lyme borreliosis in the clinical setting, including doxycycline, tetracycline, ceftriaxone, and cefotaxime. Materials and methods Isolates The susceptibility of a total of 16 isolates belonging to 5 human pathogenic species of the B. burgdorferi s.l. complex as well as 2 B. valaisiana and 2 B. lusitaniae isolates were tested. The clinical, geographic, and phenotypic characteristics of 12 of the tested isolates (Table 1) have been previously described (Hunfeld et al., 2000a, 2001, 2003; Morgenstern et al., 2009; Preac-Mursic et al., 1986). In the present study, we also tested B. lusitaniae isolate MT0407 M3 (tick isolate, Portugal), B. lusitaniae isolate IP10907 N1 (tick isolate, Germany), B. valaisiana isolate ZWU N3 (tick isolate, Germany), and B. valaisiana isolate Bv9 (tick isolate, Germany). Genospecies were identified by restriction fragment length polymorphism patterns after digestion with endonuclease MluI and by application of plasmid analysis as described previously (Belfaiza et al., 1993) or by amplifying and sequencing a 600-nucleotide fragment of the gene encoding the 16SrRNA and comparing it to the same fragment of various genospecies type strains (Richter and Matuschka, 2006). Determination of MICs MIC values were obtained by applying our previously described standardized colorimetric microdilution method Table 1 Individual antibiotic susceptibilities of 16 B. burgdorferi s.l. isolates to tigecycline, doxycycline, tetracycline, ceftriaxone, and cefotaxime (MICs and MBCs in milligram per liter) a. Antibiotic substances (MIC and MBC in mg/l) b Isolates Tigecycline Doxycycline Tetracycline Ceftriaxone Cefotaxime MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC B. burgdorferi s.s. B31-e2 r r LW2 r > r r r B. bavariensis PBi r r B. garinii G1 r r PSth r r B. afzelii FEM1 r0.016 ND EB1 r r r PKo r Z16 B. spielmanii A14S r r r PSigII r r r0.125 Z16 TIsar2 r0.016 ND r r B. valaisiana Bv9 r0.016 ND r r ZWU N3 r r0.125 Z16 B. lusitaniae IP10907 N1 r r MT0407 M3 r r Medium controls c, S. aureus (ATCC 29213) Median MIC in BSK MIC range in BSK r CLSI range E. coli (ATCC 25922) Median MIC in BSK medium r0.125 MIC range in BSK r0.125 CLSI range ND, not determined. a Antimicrobial susceptibility was determined on 3 different days, and MIC and MBC values for each isolate were reported as the median of 3 experiments. b The test ranges (in mg/l) were as follows: tigecycline: ; doxycycline: ; tetracycline: ; ceftriaxone: ; cefotaxime: c To investigate significant antibiotic medium interaction, MICs for S. aureus (ATCC 29213) and E. coli (ATCC 25922) were determined on 3 different days, referring to the CLSI method (CLSI, 2006) except for the use of BSK and preincubation of the antibiotic medium test preparation for 48 h before testing. Results were reported as the median of all 3 experiments.
3 32 L. Ates et al. / Ticks and Tick-borne Diseases 1 (2010) (Hunfeld et al., 2000a, 2000b). The antibiotic substances used were provided in lyophilized form on 96-well microtiter plates in serially diluted concentrations. The plates were supplied and quality controlled by the manufacturer (Merlin GmbH, Bornheim- Hersel, Germany). An inoculum (200 ml) of borreliae/well, in the log phase of growth, was incubated in Barbour-Stoenner- Kelly (BSK) medium (Preac-Mursic et al., 1986) supplemented with phenol red for 72 h at 33 1C. The absorbance of the test medium was measured at 0, 24, 48, and 72 h using a spectrophotometer (PowerWave 200, Bio-Tec Instruments, USA), and growth curves were calculated by utilizing a software-assisted method (MicroWin 3.0, Mikrotek Germany). Growth of samples and controls was determined for each well based on the decrease of absorbance after 72 h (E t72 ) in comparison to the initial absorbance values (E t0 ). A sample was judged to exhibit growth if the decrease from E t0 to E t72 accounted for more than 10% (Hunfeld et al., 2000b). The lowest concentration at which an isolate failed to grow in the presence of antibiotics was interpreted as the colorimetric MIC (Hunfeld et al., 2000b). Every substance was tested in triplicate on different days, but all substances were tested in parallel to each other, together with a control without antibiotic substance and a control without borreliae. The reported MIC is the median of all 3 independent experiments performed. As an additional quality control measure and to exclude significant antibiotic medium interactions, the method was also applied using Escherichia coli ATCC and Staphylococcus aureus ATCC in triplicate experiments following the CLSI (formerly NCCLS) standard protocols except for preincubation of the used antibiotic BSK preparation for 48 h before testing (CLSI 2006). Determination of MBCs Conventional MBC values of doxycycline, tetracycline, ceftriaxone, and cefotaxime were determined for at least one isolate of each genospecies by obtaining aliquots of 18 ml from each well without growth after 72 h and transferring these samples into vials containing 1332 ml of fresh BSK medium (dilution factor 1:75) (Hunfeld et al., 2000b). Due to the very low MIC values measured for tigecycline, an aliquot of 1.8 ml was transferred into 1348 ml of BSK (dilution factor 1:750) for this agent. Subcultures were then incubated at 33 1C for another 3 weeks. After slight agitation of the medium, 10 microscopical fields were examined for the presence or absence of viable spirochetes using dark-field microscopy (Carl Zeiss MicroImaging, Göttingen, Germany). Time-kill experiments Time-kill experiments were performed by culturing B. afzelii isolate EB1 in the presence of 0.016, 0.03, 0.25, and 2 mg/l tigecycline or ceftriaxone as described in the MIC experiments. The time-kill curve was constructed by counting the number of viable spirochetes under a dark-field microscope using a KOVA counting chamber (Hycor Biomedical inc., Garden grove, CA) after 0, 24, 48, 72, and 96 h. Experiments were performed in duplicate and the data are depicted as the average of 2 experiments as described recently (Kraiczy et al., 2001). The concentration of the antibiotic agent that inhibited growth of the inoculum for 72 h was defined as the MIC. The concentration that achieved a 43 log 10 reduction of the inoculum after 72 h was defined as the MBC (Kraiczy et al., 2001). Statistics To detect possible variations in the antibiotic susceptibility pattern of the different borrelial genospecies, all MIC and MBC values were analyzed for intragenospecies-specific differences applying the Kruskal-Wallis test. Calculations were performed with the statistical program BIAS, version (Epsilon Verlag, Hochheim, Germany). Results MIC determination When comparing antibiotic activities of the different substances against the tested isolates, the rank order of in vitro activity against all tested borrelial genospecies considering the median MICs of the individual substances for all tested isolates in milligram per liter was as follows: tigecycline (MIC 90 : r0.016 mg/l), ceftriaxone (MIC 90 : 0.03 mg/l), cefotaxime (MIC 90 : r0.125 mg/l), doxycycline (MIC 90 : 0.25 mg/l), tetracycline (MIC 90 : 0.25 mg/l) (Table 1). The most active antibiotic agent was tigecycline exhibiting an MIC of r0.016 mg/l in every tested isolate. Doxycycline and tetracycline had identical median MIC values, but since the average sensitivity for doxycycline in the tested isolates was lower, doxycycline was considered the more active substance. Antibiotic susceptibilities between the 7 tested genospecies did not differ significantly (Kruskal-Wallis test, po0.05). In addition, no significant MIC deviations attributable to interactions of the tested antimicrobial agents with components of the BSK medium were detected in our quality control experiments with the reference organisms S. aureus ATCC and E. coli ATCC for any of the antibiotics used (Table 1). MBC determination The MBC (defined as 100% killing) value of each isolate was obtained after a 72-h exposure to the antibiotic substances followed by an additional 3-week incubation of subcultures. When taking the median MBCs of all tested isolates in milligram per liter into account, the rank order of MBC 90 s in the tested isolates was: tigecycline (0.5 mg/l), ceftriaxone (2 mg/l), tetracycline (16 mg/l), doxycycline (16 mg/l), cefotaxime (Z16 mg/l) (Table 1). Time-kill experiments The acitivity of tigecycline and ceftriaxone against the B. afzelii isolate EB1 was further examined by time-kill experiments. Tigecycline inhibited growth of the initial inoculum for 72 h at a concentration of mg/l, whereas ceftriaxone required concentrations of 0.03 mg/l (Fig. 1). Tigecycline achieved a 43 log 10 - unit reduction of the initial inoculum after 24 h at a concentration of 0.25 mg/l, whereas in ceftriaxone a concentration of 2 mg/l was needed. Discussion Doxycycline, and occasionally other tetracyclines, are frequently administered drugs for the treatment of early Lyme borreliosis (Ljostad et al., 2008) and have shown to be effective in the majority of clinical cases (Smith et al., 2002; Wormser et al., 2003). However, clinical treatment failures in early Lyme borreliosis occur in 5 10% of all patients including
4 L. Ates et al. / Ticks and Tick-borne Diseases 1 (2010) Borrelia /well *10 6 Borrelia /well * Time (h) Control mg/l 0.03 mg/l 0.25 mg/l 2 mg/l Time (h) Control mg/l 0.03 mg/l 0.25 mg/l 2 mg/l Fig. 1. Time-kill curves of B. afzelii isolate EB1 cultured with different concentrations of tigecycline (Fig. 1A), or ceftriaxone (Fig. 1B). Concentrations for ceftriaxone were chosen as half the MIC (0.016 mg/l), the MIC (0.03 mg/l), 8 times the MIC (0.25 mg/l), and the MBC (2 mg/l) as defined by the microdilution test method (Table 1). Concentrations for tigecycline were mg/l corresponding to the MIC (growth inhibition of the initial inoculum), and 0.25 mg/l corresponding to the MBC (>3 log 10 reduction of the initial inoculum after 72 h). Two experiments were performed in parallel. Depicted is the mean of the 2 independent experiments. doxycycline-treated individuals (Ljostad et al., 2008; Preac- Mursic et al., 1989; Smith et al., 2002; Strle et al., 1995; Wormser et al., 2003). The clinical success rate in patients with early or late neuroborreliosis that were treated with doxycycline or ceftriaxone ranges between 33 and 66% (Kaiser, 2004; Ljostad et al., 2008). Doxycycline seems to be as effective as ceftriaxone in European patients affected by neuroborreliosis (Ljostad et al., 2008). However, treatment failures may be more likely in later stages of Lyme borreliosis than in the early phase characterized by erythema migrans or neuroborreliosis (Steere, 2001). In recent years, new substances for the treatment of bacterial infections have become available. In our present study, we performed in vitro susceptibility testing experiments with tigecycline, a new tetracycline and a structural analog of minocycline. Tigecycline was recently reported to be effective in vitro against B. burgdorferi (Yang et al., 2009). However, data on its in vitro effectiveness against a wider range of Borrelia isolates under standardized test conditions are missing. Here, for the first time, the in vitro activity of tigecycline was tested in well-controlled assays and compared to other clinically relevant antibiotics. In our present study, tigecycline clearly had a low MIC 90 (r0.016 mg/l) for all tested isolates. In fact, tigecycline was more active than doxycycline (MIC 90 : 0.25 mg/l) and appeared even more active in vitro than ceftriaxone (MIC 90 : 0.03 mg/l) for all isolates tested. Furthermore, tigecycline was the most borreliacidal compound of all tested substances resulting in an MBC 90 of 0.5 mg/l for the tested isolates. Taking all MBC 90 values into account, tigecycline was 4 times more effective in vitro than the second most active antibiotic, ceftriaxone (MBC 90 : 2 mg/l), and up to 32 times more effective than doxycycline (range of MBCs: 8 16 mg/l). Our observation of a high in vitro activity of tigecycline was further confirmed by time-kill experiments using the B. afzelii isolate EB1. Tigecycline inhibited the growth of the initial inoculum at mg/l and reduced the inoculum by 43 log 10 at 0.25 mg/l after 72 h of incubation, thereby corresponding to the low MIC 90 and MBC 90 values as determined by our microdilution susceptibility experiments. As depicted in Table 1, the in vitro susceptibility values of the other tested tetracyclines and cephalosporins were found to be in good accordance with values published in the recent literature (Hunfeld and Brade, 2006). Moreover, our quality control experiments clearly confirmed that in vitro test results were not significantly hampered by possible interactions of the antibiotic substances with the BSK medium. Interestingly, tigecycline was shown to be more effective than related classical tetracyclines in many Gram-positive and Gramnegative bacteria including multi-drug resistant pathogens with RND-efflux pumps (Greer, 2006). Such RND-type efflux pumps are prevalent in a wide variety of other Gram-negative bacteriae, such as E. coli and Acinetobacter baumanii, where they appear to decrease the susceptibility of these organisms to a large number of antibiotic agents including tetracyclines (Chau et al., 2004). Interestingly, such a mechanism of antibiotic resistance has recently been described also for B. burgdorferi demonstrating the efflux of antibiotics from thespirochetebyuseofaresistancenodulation-celldivision(rnd) type efflux pump called BesABC (Bunikis et al., 2008). A knockout of BesC in a genetically modified B. burgdorferi s.s. strain was demonstrated to result in an increased susceptibility to multiple classes of antibiotics used in the therapy of Lyme borreliosis. For tetracycline, an 8-fold decrease of the MIC 90 (0.31 mg/l in the wildtype strain vs mg/l in the BesC knockout strain) and a 15-fold decrease of the MBC (2.5 mg/l in the wild-type strain vs mg/l in the BesC knockout strain) was observed using our standardized susceptibility-testing assay (Bunikis et al., 2008). One of the proposed reasons for the increased activity of tigecycline against borrelia compared to classical tetracyclines as observed in our study may be the fact that tigecycline is obviously more resistant to efflux as mediated by RND-type efflux systems than are the classical tetracyclines (Greer, 2006; Zhanel et al., 2004). Taking into consideration the results of our study, the susceptibility testing of borrelial mutants with altered tetracycline resistance against tigecycline would be a very interesting future approach of antibiotic research in borrelia. Furthermore, tigecycline has a much larger volume of distribution V d compared to the classical tetracyclines (Zhanel et al., 2004) (>10 L/kg vs L/kg) which is, however, similar to the V d of ceftriaxone (Patel and Kaplan, 1984). These considerations and its high in vitro activity against Borrelia clearly warrant further clinical studies on tigecyline in the treatment of disseminated late manifestations of Lyme borreliosis, i.e. arthritis or acrodermatitis chronica atrophicans. In summary, we have further confirmed that tigecycline is very effective in vitro against a wide variety of B. burgdorferi s.l. isolates. In fact, it actually appears more effective in vitro than other agents that are frequently used for the treatment of Lyme
5 34 L. Ates et al. / Ticks and Tick-borne Diseases 1 (2010) borreliosis. Taking together, tigecycline may constitute a novel candidate for the treatment of more severe cases of disseminated or late stage Lyme borreliosis. Of course, this suggestion clearly requires further research in controlled clinical trials. References Belfaiza, J., Postic, D., Bellenger, E., Baranton, G., Girons, I.S., Genomic fingerprinting of Borrelia burgdorferi sensu lato by pulsed-field gel electrophoresis. J. Clin. Microbiol. 31, Bunikis, I., Denker, K., Ostberg, Y., Andersen, C., Benz, R., Bergström, S., An RND-type efflux system in Borrelia burgdorferi is involved in virulence and resistance to antimicrobial compounds. PLoS Pathog. 4, e CLSI, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved standard, Seventh ed., M7-A7. CLSI, Wayne, Pa. Chau, S.L., Chu, Y.W., Houang, E.T., Novel resistance-nodulation-cell division efflux system AdeDE in Acinetobacter genomic DNA group 3. Antimicrob. Agents Chemother. 48, Greer, N.D., Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics: Bayl. Univ. Med. Cent. Proc. 19, Hodzic, E., Feng, S., Holden, K., Freet, K.J., Barthold, S.W., Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob. Agents Chemother. 52, Hunfeld, K.-P., Brade, V., Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: What we know, what we don t know, and what we need to know. Wien Klin Wochenschr. 118, Hunfeld, K.-P., Kraiczy, P., Wichelhaus, T.A., Schäfer, V., Brade, V., 2000a. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Int. J. Antimicrob. Agents 15, Hunfeld, K.-P., Kraiczy, P., Wichelhaus, T.A., Schäfer, V., Brade, V., 2000b. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur. J. Clin. Microbiol. Infect. Dis. 19, Hunfeld, K.-P., Rodel, R., Wichelhaus, T.A., In vitro activity of eight oral cephalosporins against Borrelia burgdorferi. Int. J. Antimicrob. Agents 21, Hunfeld, K.-P., Ružić-Sabljić, E., Norris, D.E., Kraiczy, P., Strle, F., In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob. Agents Chemother. 49, Hunfeld, K.-P., Wichelhaus, T.A., Kekoukh, E., Molitor, M., Kraiczy, P., Brade, V., In vitro susceptibility of the Borrelia burgdorferi sensu lato complex to ABT-773, a novel ketolide. J. Antimicrob. Chemother. 48, Jamal, W.Y., Al Hashem, G., Khodakhast, F., Rotimi, V.O., Comparative in vitro activity of tigecycline and nine other antibiotics against gram-negative bacterial isolates, including ESBL-producing strains. J. Chemother. 21, Kaiser, R., Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone. Nervenarzt 75, (in German). Kraiczy, P., Weigand, J., Wichelhaus, T.A., Heisig, P., Backes, H., Schäfer, V., Acker, G., Brade, V., Hunfeld, K.-P., In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi. Antimicrob. Agents Chemother. 45, Ljostad, U., Skogvoll, E., Eikeland, R., Midgard, R., Skarpaas, T., Berg, A., Mygland, A., Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 7, Loewen, P.S., Marra, C.A., Marra, F., Systematic review of the treatment of early Lyme disease. Drugs 57, Margos, G., Vollmer, S.A., Cornet, M., Garnier, M., Fingerle, V., Wilske, B., Bormane, A., Vitorino, L., Collares-Pereira, M., Drancourt, M., Kurtenbach, K., A new Borrelia species defined by multilocus sequence analysis of housekeeping genes. Appl. Environ. Microbiol. 75, Miklossy, J., Kasas, S., Zurn, A.D., McCall, S., Yu, S., McGeer, P.L., Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J. Neuroinflammation. 5, 40. Morgenstern, K., Baljer, G., Norris, D.E., Kraiczy, P., Hanssen-Hübner, C., Hunfeld, K.-P., In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. Antimicrob. Agents Chemother. 53, Patel, I.H., Kaplan, S.A., Pharmacokinetic profile of ceftriaxone in man. Am. J. Med. 77, Preac-Mursic, V., Weber, K., Pfister, H.W., Wilske, B., Gross, B., Baumann, A., Prokop, J., Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 17, Preac-Mursic, V., Wilske, B., Schierz, G., European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility: Zentralbl. Bakteriol. Mikrobiol. Hyg. [A] 263, Smith, R.P., Schoen, R.T., Rahn, D.W., Sikand, V.K., Nowakowski, J., Parenti, D.L., Holman, M.S., Persing, D.H., Steere, A.C., Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann. Intern. Med. 136, Richter, D., Matuschka, F.R., Perpetuation of the Lyme disease spirochete Borrelia lusitaniae by lizards. Appl. Environ. Microbiol. 72, Stanek, G., O Connell, S., Cimmino, M., Aberer, E., Kristoweritsch, W., Granström, M., Guy, E., Gray, J., European Union concerted action on risk assessment in Lyme borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr. 108, Steere, A.C., Lyme disease. N. Engl. J. Med. 345, Strle, F., Cheng, Y., Cimperman, J., Maraspin, V., Lotric-Furlan, S., Nelson, J.A., Picken, M.M., Ružić-Sabljić, E., Picken, R.N., Persistence of Borrelia burgdorferi sensu lato in resolved erythema migrans lesions. Clin. Infect. Dis. 21, Weinstein, A., Britchkov, M., Lyme arthritis and post-lyme disease syndrome. Curr. Opin. Rheumatol. 14, Wormser, G.P., Ramanathan, R., Nowakowski, J., McKenna, D., Holmgren, D., Visintainer, P., Dornbush, R., Singh, B., Nadelman, R.B., Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 138, Yang, X., Nguyen, A., Qiu, D., Luft, B.J., In vitro activity of tigecycline against multiple strains of Borrelia burgdorferi. J. Antimicrob. Chemother. 63, Zhanel, G.G., Decorby, M., Nichol, K.A., Baudry, P.J., Karlowsky, J.A., Lagace-Wiens, P.R., McCracken, M., Mulvey, M.R., Hoban, D.J., Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study ( ). Can. J. Infect. Dis. Med. Microbiol. 19, Zhanel, G.G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J.A., Hoban, D.J., The glycylcyclines: a comparative review with the tetracyclines. Drugs 64,
Tel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationBorrelia burgdorferi, to Four Antimicrobial Agents
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1987, p. 164-167 0066-48041871020164-04$02.00/0 Copyright 1987, American Society for Microbiology Vol. 31, No. 2 In Vitro and In Vivo Susceptibility of the Lyme
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationLyme disease: diagnosis and management
National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final
More informationThe War on Lyme Patients
Who has declared war on Lyme patients? The War on Lyme Patients Infectious Disease Society of America (IDSA) Douglas W. Fearn Lyme Disease Association of Southeastern Pennsylvania, Inc. Infectious Disease
More informationEffectiveness of doxycycline for lyme disease
Effectiveness of doxycycline for lyme disease The Borg System is 100 % Effectiveness of doxycycline for lyme disease Mar 30, 2016. How long to treat patients with Lyme remains an issue of controversy.
More informationDynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
2011 International Conference on Biomedical Engineering and Technology IPCBEE vol.11 (2011) (2011) IACSIT Press, Singapore Dynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
More informationRecommended for Implementation at Step 7 of the VICH Process on 15 December 2004 by the VICH Steering Committee
VICH GL27 (ANTIMICROBIAL RESISTANCE: PRE-APPROVAL) December 2003 For implementation at Step 7 - Final GUIDANCE ON PRE-APPROVAL INFORMATION FOR REGISTRATION OF NEW VETERINARY MEDICINAL PRODUCTS FOR FOOD
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationRandall Singer, DVM, MPVM, PhD
ANTIBIOTIC RESISTANCE Randall Singer, DVM, MPVM, PhD Associate Professor of Epidemiology Department of Veterinary and Biomedical Sciences University of Minnesota Overview How does resistance develop? What
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationPractice Guidelines for the Treatment of Lyme Disease
S1 GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA Practice Guidelines for the Treatment of Lyme Disease Gary P. Wormser, 1 Robert B. Nadelman, 1 Raymond J. Dattwyler, 2 David T. Dennis, 6 Eugene
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationOptimal Use Report CADTH. Canadian Agency for Drugs and Technologies in Health. Agence canadienne des médicaments et des technologies de la santé
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé Optimal Use Report CADTH Volume 2, Issue 2A April 2012 Screening, Isolation, and Decolonization
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
More informationPresence of extended spectrum β-lactamase producing Escherichia coli in
1 2 Presence of extended spectrum β-lactamase producing Escherichia coli in wild geese 3 4 5 A. Garmyn* 1, F. Haesebrouck 1, T. Hellebuyck 1, A. Smet 1, F. Pasmans 1, P. Butaye 2, A. Martel 1 6 7 8 9 10
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationMultidrug Resistant Bacteria in 200 Patients of Moroccan Hospital
IOSR Journal Of Humanities And Social Science (IOSR-JHSS) Volume 22, Issue 8, Ver. 7 (August. 2017) PP 70-74 e-issn: 2279-0837, p-issn: 2279-0845. www.iosrjournals.org Multidrug Resistant Bacteria in 200
More informationTitle: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic
AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.0070-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationTyphoid fever - priorities for research and development of new treatments
Typhoid fever - priorities for research and development of new treatments Isabela Ribeiro, Manica Balasegaram, Christopher Parry October 2017 Enteric infections Enteric infections vary in symptoms and
More informationMethicillin and Clindamycin resistance in biofilm producing staphylococcus aureus isolated from clinical specimens
Original article Methicillin and Clindamycin resistance in biofilm producing staphylococcus aureus isolated from clinical specimens Pankaj A. Joshi, Dhruv K.Mamtora,. Neeta PJangale., Meena N.Ramteerthakar,
More informationDRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION. Cara Wilder Ph.D. Technical Writer March 13 th 2014
DRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION Cara Wilder Ph.D. Technical Writer March 13 th 2014 ATCC Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas,
More informationInhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology Zeina Alkudmani Chemotherapy Definitions The use of any chemical (drug) to treat any disease or condition. Chemotherapeutic Agent Any drug
More informationReceived 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationUrban Landscape Epidemiology - Ticks and the City -
Ticks and the City Urban Landscape Epidemiology - Ticks and the City - Dania Richter & Boris Schröder-Esselbach Institute of Geoecology, Technische Universität Braunschweig & Franz-Rainer Matuschka, Universität
More informationSURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS
SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS Adrienn Hanczvikkel 1, András Vígh 2, Ákos Tóth 3,4 1 Óbuda University, Budapest,
More informationAntibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance
More informationService Delivery and Safety Department World Health Organization, Headquarters
Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationIn vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains
Eur J Clin Microbiol Infect Dis (2010) 29:503 507 DOI 10.1007/s10096-010-0886-2 ARTICLE In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationAntimicrobials. Antimicrobials
Antimicrobials For more than 50 years, antibiotics have come to the rescue by routinely producing rapid and long-lasting miracle cures. However, from the beginning antibiotics have selected for resistance
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(8):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.378
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationPROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains
PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains 1 INTRODUCTION... 1 2 OBJECTIVES... 2 3 OUTLINE OF THE EQAS 2017... 2 3.1 Shipping, receipt and storage of strains...
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationAntibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
Antimicrobial susceptibility of Shigella, 2015 and 2016 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationBorrelia burgdorferi
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1993, p. 1115-1121 0066-4804/93/051115-07$02.00/0 Copyright 1993, American Society for Microbiology Vol. 37, No. 5 In Vitro Activity of Vancomycin against the
More informationOriginal Article. Suthan Srisangkaew, M.D. Malai Vorachit, D.Sc.
Original Article Vol. 21 No.1 The optimum agent for ESBL screening and confirmatory tests:- Srisangkaew S & Vorachit M. 1 The Optimum Agent for Screening and Confirmatory Tests for Extended-Spectrum Beta-Lactamases
More informationLyme Disease Prevention and Treatment Information for Patients
What is Lyme disease? Lyme disease is an infection caused by a bacteria carried by some ticks. It can occur after a black-legged or deer tick bite. Lyme disease cannot be transferred from one person to
More informationQ1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.
Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. C. difficile rarely causes problems, either in healthy adults or in infants.
More informationProject Summary. Impact of Feeding Neomycin on the Emergence of Antibiotic Resistance in E. coli O157:H7 and Commensal Organisms
Project Summary Impact of Feeding Neomycin on the Emergence of Antibiotic Resistance in E. coli O157:H7 and Commensal Organisms Principal Investigators: Mindy Brashears, Ph.D., Texas Tech University Guy
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationAntibacterial activity of Stephania suberosa extract against methicillin-resistant Staphylococcus aureus
B-O-021 Antibacterial activity of Stephania suberosa extract against methicillin-resistant Staphylococcus aureus Nongluk Autarkool *a, Yothin Teethaisong a, Sajeera Kupittayanant b, Griangsak Eumkeb a
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationBIOLACTAM. Product Description. An innovative in vitro diagnostic for the rapid quantitative determination of ß-lactamase activity
BIOLACTAM www.biolactam.eu An innovative in vitro diagnostic for the rapid quantitative determination of ß-lactamase activity 1.5-3h 20 Copyright 2014 VL-Diagnostics GmbH. All rights reserved. Product
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationResistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints
...PRESENTATIONS... Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints Angela B. Brueggemann, MS; and Gary V. Doern, PhD Presentation Summary Streptococcus pneumoniae
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationGenetic diversity of Borrelia burgdorferi sensu lato isolates obtained from Ixodes ricinus ticks collected in Slovakia
Published in European Journal of Epidemiology 15, issue 7, 665-669, 1999 which should be used for any reference to this work 1 Genetic diversity of Borrelia burgdorferi sensu lato isolates obtained from
More informationActivity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City
Journal of Antimicrobial Chemotherapy Advance Access published July 31, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq278 Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More information